Aggressive lymphoma: Improving treatment outcome with rituximab

Bertrand Coiffier, Michael Pfreundschuh, Rolf Stahel, Julie Marie Vose, Pier L. Zinzani

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60% of patients but is curative in only about 40-50%. More aggressive and/or dose-intensified chemotherapy regimens have failed to provide significant survival advantages compared with CHOP, and may have higher toxicity. Rituximab, a chimeric monoclonal antibody to the CD20 antigen, is effective as monotherapy in aggressive lymphoma and in combination with chemotherapy has demonstrated high response rates in phase II trials. A scheduled interim analysis of a randomized, prospective trial comparing rituximab plus CHOP with CHOP alone in elderly patients with untreated diffuse large B-cell lymphoma has shown significantly better response rates and survival with rituximab plus CHOP compared with CHOP alone. These results represent the first significant improvement in overall survival over CHOP in aggressive lymphoma for over 20 years. The addition of rituximab was not associated with significant additional toxicity over that seen with CHOP alone. Ongoing studies are underway to establish whether the survival benefit of rituximab plus CHOP is seen in younger patient populations. Rituximab in combination with chemotherapy is also being evaluated as salvage treatment for patients who relapse after initial chemotherapy. In a preliminary analysis of a study in 50 patients with refractory or relapsed aggressive lymphoma, rituximab plus etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy has demonstrated promising results when used as sole salvage therapy and as an induction therapy prior to autologous stem-cell transplantation, again without significant additional toxicity. [

Original languageEnglish (US)
Pages (from-to)S43-S50
JournalAnti-Cancer Drugs
Volume13
Issue numberSUPPL. 2
DOIs
StatePublished - Nov 2002

Fingerprint

Lymphoma
Drug Therapy
Salvage Therapy
Vincristine
Prednisone
Combination Drug Therapy
Doxorubicin
Cyclophosphamide
Survival
CD20 Antigens
Lymphoma, Large B-Cell, Diffuse
Stem Cell Transplantation
Etoposide
Rituximab
Survival Rate
Monoclonal Antibodies
Recurrence
Therapeutics
Population

Keywords

  • Aggressive lymphoma
  • Immunochemotherapy
  • Rituximab
  • Salvage therapy
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Coiffier, B., Pfreundschuh, M., Stahel, R., Vose, J. M., & Zinzani, P. L. (2002). Aggressive lymphoma: Improving treatment outcome with rituximab. Anti-Cancer Drugs, 13(SUPPL. 2), S43-S50. https://doi.org/10.1097/00001813-200211002-00007

Aggressive lymphoma : Improving treatment outcome with rituximab. / Coiffier, Bertrand; Pfreundschuh, Michael; Stahel, Rolf; Vose, Julie Marie; Zinzani, Pier L.

In: Anti-Cancer Drugs, Vol. 13, No. SUPPL. 2, 11.2002, p. S43-S50.

Research output: Contribution to journalArticle

Coiffier, B, Pfreundschuh, M, Stahel, R, Vose, JM & Zinzani, PL 2002, 'Aggressive lymphoma: Improving treatment outcome with rituximab', Anti-Cancer Drugs, vol. 13, no. SUPPL. 2, pp. S43-S50. https://doi.org/10.1097/00001813-200211002-00007
Coiffier, Bertrand ; Pfreundschuh, Michael ; Stahel, Rolf ; Vose, Julie Marie ; Zinzani, Pier L. / Aggressive lymphoma : Improving treatment outcome with rituximab. In: Anti-Cancer Drugs. 2002 ; Vol. 13, No. SUPPL. 2. pp. S43-S50.
@article{b8fcfa0e9eb0483b90060158ad1db7d4,
title = "Aggressive lymphoma: Improving treatment outcome with rituximab",
abstract = "The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60{\%} of patients but is curative in only about 40-50{\%}. More aggressive and/or dose-intensified chemotherapy regimens have failed to provide significant survival advantages compared with CHOP, and may have higher toxicity. Rituximab, a chimeric monoclonal antibody to the CD20 antigen, is effective as monotherapy in aggressive lymphoma and in combination with chemotherapy has demonstrated high response rates in phase II trials. A scheduled interim analysis of a randomized, prospective trial comparing rituximab plus CHOP with CHOP alone in elderly patients with untreated diffuse large B-cell lymphoma has shown significantly better response rates and survival with rituximab plus CHOP compared with CHOP alone. These results represent the first significant improvement in overall survival over CHOP in aggressive lymphoma for over 20 years. The addition of rituximab was not associated with significant additional toxicity over that seen with CHOP alone. Ongoing studies are underway to establish whether the survival benefit of rituximab plus CHOP is seen in younger patient populations. Rituximab in combination with chemotherapy is also being evaluated as salvage treatment for patients who relapse after initial chemotherapy. In a preliminary analysis of a study in 50 patients with refractory or relapsed aggressive lymphoma, rituximab plus etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy has demonstrated promising results when used as sole salvage therapy and as an induction therapy prior to autologous stem-cell transplantation, again without significant additional toxicity. [",
keywords = "Aggressive lymphoma, Immunochemotherapy, Rituximab, Salvage therapy, Survival",
author = "Bertrand Coiffier and Michael Pfreundschuh and Rolf Stahel and Vose, {Julie Marie} and Zinzani, {Pier L.}",
year = "2002",
month = "11",
doi = "10.1097/00001813-200211002-00007",
language = "English (US)",
volume = "13",
pages = "S43--S50",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Aggressive lymphoma

T2 - Improving treatment outcome with rituximab

AU - Coiffier, Bertrand

AU - Pfreundschuh, Michael

AU - Stahel, Rolf

AU - Vose, Julie Marie

AU - Zinzani, Pier L.

PY - 2002/11

Y1 - 2002/11

N2 - The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60% of patients but is curative in only about 40-50%. More aggressive and/or dose-intensified chemotherapy regimens have failed to provide significant survival advantages compared with CHOP, and may have higher toxicity. Rituximab, a chimeric monoclonal antibody to the CD20 antigen, is effective as monotherapy in aggressive lymphoma and in combination with chemotherapy has demonstrated high response rates in phase II trials. A scheduled interim analysis of a randomized, prospective trial comparing rituximab plus CHOP with CHOP alone in elderly patients with untreated diffuse large B-cell lymphoma has shown significantly better response rates and survival with rituximab plus CHOP compared with CHOP alone. These results represent the first significant improvement in overall survival over CHOP in aggressive lymphoma for over 20 years. The addition of rituximab was not associated with significant additional toxicity over that seen with CHOP alone. Ongoing studies are underway to establish whether the survival benefit of rituximab plus CHOP is seen in younger patient populations. Rituximab in combination with chemotherapy is also being evaluated as salvage treatment for patients who relapse after initial chemotherapy. In a preliminary analysis of a study in 50 patients with refractory or relapsed aggressive lymphoma, rituximab plus etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy has demonstrated promising results when used as sole salvage therapy and as an induction therapy prior to autologous stem-cell transplantation, again without significant additional toxicity. [

AB - The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60% of patients but is curative in only about 40-50%. More aggressive and/or dose-intensified chemotherapy regimens have failed to provide significant survival advantages compared with CHOP, and may have higher toxicity. Rituximab, a chimeric monoclonal antibody to the CD20 antigen, is effective as monotherapy in aggressive lymphoma and in combination with chemotherapy has demonstrated high response rates in phase II trials. A scheduled interim analysis of a randomized, prospective trial comparing rituximab plus CHOP with CHOP alone in elderly patients with untreated diffuse large B-cell lymphoma has shown significantly better response rates and survival with rituximab plus CHOP compared with CHOP alone. These results represent the first significant improvement in overall survival over CHOP in aggressive lymphoma for over 20 years. The addition of rituximab was not associated with significant additional toxicity over that seen with CHOP alone. Ongoing studies are underway to establish whether the survival benefit of rituximab plus CHOP is seen in younger patient populations. Rituximab in combination with chemotherapy is also being evaluated as salvage treatment for patients who relapse after initial chemotherapy. In a preliminary analysis of a study in 50 patients with refractory or relapsed aggressive lymphoma, rituximab plus etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy has demonstrated promising results when used as sole salvage therapy and as an induction therapy prior to autologous stem-cell transplantation, again without significant additional toxicity. [

KW - Aggressive lymphoma

KW - Immunochemotherapy

KW - Rituximab

KW - Salvage therapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0036878677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036878677&partnerID=8YFLogxK

U2 - 10.1097/00001813-200211002-00007

DO - 10.1097/00001813-200211002-00007

M3 - Article

C2 - 12710590

AN - SCOPUS:0036878677

VL - 13

SP - S43-S50

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - SUPPL. 2

ER -